The nucleophosmin (NPM1) gene encodes for a multifunctional protein with prominent
nucleolar localization that shuttles between nucleus and cytoplasm. NPM1 mutations …

The interleukin-3 receptor alpha chain (IL-3Rα), more commonly referred to as CD123, is
widely overexpressed in various hematological malignancies, including acute myeloid …

Measurable residual disease (MRD) is an important biomarker in acute myeloid leukemia
(AML) that is used for prognostic, predictive, monitoring, and efficacy-response …

The treatment landscape of acute myeloid leukemia (AML) is evolving, with promising
therapies entering clinical translation, yet patient responses remain heterogeneous, and …

PURPOSE Patients with acute myeloid leukemia (AML) in remission remain at risk for
relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable …

Acute myeloid leukemia may be characterized by a fraction of leukemia stem cells (LSCs)
that sustain disease propagation eventually leading to relapse. Yet, the contribution of LSCs …

Monitoring of measurable residual disease (MRD) provides prognostic information in
patients with Nucleophosmin1-mutated (NPM1 mut) acute myeloid leukemia (AML) and …

Transposable elements or transposons are major players in genetic variability and genome
evolution. Aberrant activation of long interspersed element-1 (LINE-1 or L1) …

Based on the individual genetic profile, acute myeloid leukemia (AML) patients are classified
into clinically meaningful molecular subtypes. However, the mutational profile within these …

Background Deep learning has emerged as a versatile approach for predicting complex
biological phenomena. However, its utility for biological discovery has so far been limited …